Attention Deficit Disorder With Hyperactivity (ADHD)JUSTICE-TDAHNCT07487155
Unified Junction of Care, Integrated Treatments and Team Coordination for ADHD in Prison Settings With Substance Use Disorder
A study testing Workshop in people with Attention Deficit Disorder With Hyperactivity (ADHD) and Substance Use Disorder (SUD), run by University Hospital, Brest at 1 site in France.
Trial summary
Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Attention Deficit Disorder With Hyperactivity (ADHD), Substance Use Disorder (SUD)
- What is being tested?
- Workshop
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 39 participants
- Where
- 1 siteFrance
- Study dates
- 3 Aug 2026to 1 Jan 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult, under the supervision of the justice system or monitored by a correctional facility
- Diagnosis of Substance Use Disorder (SUD)
- Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
- No objection from the patient
- Affiliated with a Social Security system
Who cannot join
- Severe or decompensated psychiatric disorders
- Severe cognitive impairment
- Lack of understanding of the French language
- Refusal to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Brest
Brest, 29200
Morgane GUILLOU LANDREAT, MD, 029822342348, morgane.guillou@chu-brest.fr
Morgane GUILLOU LANDREAT, MD
About this study
Substance use disorders (SUD) and attention deficit disorder with or without hyperactivity (ADHD) are frequently co-morbid, particularly among people under court supervision. The coexistence of these disorders increases the social and legal vulnerability of individuals. Better identification of ADHD in vulnerable people with SUD is essential to improving their care. This project aims to provide appropriate support for this at-risk population.
- Being tested
- Workshop
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity, Substance-Related Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
WorkshopOther
Assess the 5 workshops, co-constructed by the scientific committee and thanks to feedback from the qualitative study
| Study group | Role | What they receive |
|---|---|---|
| Workshops | Experimental | Workshops with a small group of patients. Receives: Other: Workshop |
What is being measured
The primary outcome is the main question the study is designed to answer.
80% of patients participated in the workshops
The primary outcome measure is the acceptability of the program to participants in the pilot workshops, gathered through:
- Semi-structured pre- and post-intervention interviews
- A Likert scale
- Workshop participation rate (at least 80%)
Measured: From enrollment to the end of wordshop at 6 months
Secondary outcomes (1)
SF-12 quality of life
The secondary outcome measure will be measured by the SF-12 quality of life, before and after the 5 workshops. The SF-12 is a self-reported outcome measure assessing the impact of health on an individual's everyday life.
Measured: From enrollment to the end of wordshop at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study start3 Aug 2026
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit Disorder With Hyperactivity (ADHD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 39 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Morgane GUILLOU-LANDREAT, MD, Principal investigator, CHU Brest
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07487155
- Sponsor's protocol ID
- 29BRC25.0324 - JUSTICE-TDAH
- Other IDs
- IDRCB
- Acronym
- JUSTICE-TDAH
- Status last verified
- Aug 2026
- First submitted
- 12 Mar 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication